VTGN VistaGen Therapeutics
- 3.1100
- +0.0300+0.97%
- 3.1100
- 0.00000.00%
About VistaGen Therapeutics Company
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Company Profile
Company Executives
- Name
- Position
- Salary
- Shawn K. Singh, J.D.
- Chief Executive Officer and Director
- 947.92K
- Cynthia Lynn Anderson, C.P.A.
- Vice President and Chief Financial Officer
- 434.19K
- Joshua S. Prince, M.B.A.
- Chief Operating Officer
- 568.44K
- Reid G. Adler, J.D.
- Chief Corporate Development Officer and General Counsel
- 675.00K
- Margaret M. FitzPatrick
- Chairman of the Board
- 185.62K
- Ann M. Cunningham, M.B.A.
- Director
- 313.12K
- Joanne Curley, PhD
- Independent Director
- 113.12K
- Jon S. Saxe, J.D.,L.L.M.
- Independent Director
- 129.37K
- Dr. Jerry B. Gin, M.B.A.,PhD
- Independent Director
- 128.12K
- Mary L. Rotunno, J.D.
- Independent Director
- 128.12K
Analysis
Price Target
No Data
No Data